AI-Enabled Pathology: De-risking Oncology Drug Development

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.

At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.

Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.

This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.

At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.

Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.

On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.

‍

At this year’s Handelsblatt Live Pharma Congress 2026, our CEO Felix Faber addressed one of the industry’s most pressing challenges: the high failure rate of clinical trials.

In his session, “AI is the Insurance for Your IHC Biomarker Trial,” Felix outlined how AI-enabled pathology and reproducible biomarker analysis can help de-risk oncology drug development earlier and with greater confidence.

Manual, variable tissue analysis remains a major bottleneck in clinical development. Expert-directed AI can detect subtle signals across billions of pixels, enabling consistent biomarker assessment, improved patient stratification, and reduced development risk and cost.

Thank you to Handelsblatt Live and everyone who joined the discussion.

‍